Now Recruiting

PH 3/4 GLASSIA SAFETY, IMMUNOGENICITY, AND BRONCHOALVEOLAR LAVAGE STUDY

WHAT IS THE PURPOSE OF THIS STUDY?

The purpose of the study is 2-fold: (1) to further evaluate the safety and potential immunogenicity of GLASSIA following IV administration via in-line filtration; and, (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 mg/kg Body weight (BW)/week active A1PI protein for 25 weeks in subjects with emphysema due to congenital A1PI deficiency.

TRIAL AT A GLANCE

Condition

Alpha1-antitrypsin Deficiency

Study Intervention

GLASSIA

Possibility of Active Treatment

100%

Study Type

Interventional

Phase

Phase 3

IS THIS STUDY RIGHT FOR ME?

AGE

18 & UP

N/A

GENDERS

ACCEPTS HEALTHY VOLUNTEERS

No

PARTICIPATION DURATION/ REQUIREMENTS

The recruitment period is expected to be approximately 16 months. The duration of each participant’s participation from enrollment to participant completion (ie, last study visit) is anticipated to be approximately 8 months (unless the participant withdraws or is prematurely discontinued from the study), including:• a screening period of up to 6 weeks,• a baseline period of up to 2 weeks (for participants undergoing baseline BAL procedure),• a treatment period of 25 weeks, and• a post-treatment safety follow-up period of 7 (±3) days after the last infusion.

ENTRY CRITERIA

Inclusion Criteria:1.Male or female participants meeting the following age criteria:a.For participants who will undergo bronchoscopy/ bronchoalveolar lavage (BAL) procedures: 18 to 75 years of age at the time of screening.b.For participants who will be waived from undergoing bronchoscopy/BAL procedures: 18 years of age or older at the time of screening.2.Documented Alpha1-Proteinase Inhibitor (A1PI) genotype of Pi*Z/Z, Pi*Z/Null, Pi*Malton/Z, Pi*Null/Null, or other "at-risk" allelic combinations such as SZ (excluding MS and MZ) and an endogenous A1PI plasma levels of ≤11 μM.3.Screening levels of endogenous plasma (antigenic) A1PI of ≤11 μM may be collected at any time during the screening period for treatment-naïve participants, or following a 4 week minimum wash-out from previous augmentation therapy in treatment-experienced participants.4.Participants must have at least one of the following: clinical diagnosis of emphysema, evidence of emphysema on computerized tomography (CT) scan of the chest, and/or evidence of airway obstruction which is not completely reversed with bronchodilator treatment at the time of screening.5.If the participant is being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone ≤10 mg/day or its equivalent), the doses of the participant's medications have remained unchanged for at least 14 days prior to screening.6.The participant is a nonsmoker or has ceased smoking for a minimum of 13 weeks prior to screening (serum cotinine level at screening within normal range of a nonsmoker) and agrees to refrain from smoking throughout the course of the study. Participants with a positive cotinine test due to nicotine replacement therapy (eg, patches, chewing gum), vapor cigarettes, or snuff are eligible.7.If female of childbearing potential, the participant presents with a negative pregnancy test at screening and agrees to employ adequate birth control measures for the duration of the study.8.The participant is willing and able to comply with the requirements of the protocol.9.The participant must have pulmonary function at the time of screening meeting both of the following:a.Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥50% of predicted.b.If FEV1 is >80% predicted, then FEV1/forced vital capacity (FVC) must be <0.7.**Note: Inclusion criterion #1a and #9a are not applicable to participants who are not required to undergo the bronchoscopy/BAL procedures.

Exclusion Criteria:1.The participant is experiencing or has a history of clinically significant pulmonary disease (other than chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, mild bronchiectasis, and stable asthma).2.The participant is experiencing or has a history of chronic severe cor pulmonale (resting mean pulmonary artery pressure ≥40 millimeter(s) of mercury (mm Hg)).3.The participant routinely produces more than 1 tablespoon of sputum per day.4.The participant has a history of frequent pulmonary exacerbations (greater than 2 moderate or severe exacerbations within 52 weeks prior to screening.5.The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be re-screened 4 weeks after the clinical resolution of an exacerbation).6.The participant has clinically significant abnormalities (other than emphysema, chronic bronchitis, or mild bronchiectasis) detected on chest X-ray or CT scan at the time of screening. (Past records obtained within 52 weeks prior to screening may be used, if available.)7.The participant has clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG) performed at the time of screening. (Past records obtained within 26 weeks prior to screening may be used, if available.)8.The participant has clinically significant congestive heart failure with New York Heart Association (NYHA) Class III/IV symptoms.9.The participant is experiencing an active malignancy or has a history of malignancy within 5 years prior to screening, with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment.10.The participant has a history of lung or other organ transplant, is currently on a transplant list, or has undergone major lung surgery.11.The participant is receiving long-term around-the-clock oxygen supplementation. (The following are allowed: short-term use of oxygen supplementation [eg, for the management of acute COPD exacerbation], oxygen supplementation required during night time only, and supplemental oxygen (O2) with continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP]).12.Known history of hypersensitivity following infusions of human blood or blood components.13.Immunoglobulin A (IgA) deficiency (<8 mg/dL at screening).14.Abnormal clinical laboratory results obtained at the time of screening meeting any of the following criteria:a.Serum alanine aminotransferase (ALT) >3.0 times upper limit of normal (ULN)b.Serum total bilirubin >2.0 times ULNc.>2+proteinuria on urine dipstick analysisd.Serum creatinine >2.0 times ULNe.Absolute neutrophil count (ANC) <1500 cells/mm^3f.Hemoglobin (Hgb) <9.0 g/dLg.Platelet count <100,000/mm^315.Ongoing active infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) Type 1 or 2 infection at the time of screening.16.The participant has any clinically significant medical, psychiatric, or cognitive illness, or any other uncontrolled medical condition (eg, unstable angina, transient ischemic attack) that, in the opinion of the investigator, would impede the participant's ability to comply with the study procedures, pose increased risk to the participant's safety, or confound the interpretation of study results.17.The participant has participated in another clinical study involving an investigational product or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study.18.The participant is a family member or employee of the investigator.19.If female, the participant is nursing at the time of screening.20.The participant has contraindication(s) to bronchoscopy such as recent myocardial infarction, unstable angina, other cardiopulmonary instability, tracheal obstruction or stenosis, moderate to severe hypoxemia or any degree of hypercapnia, unstable asthma, Stage 4 or 5 chronic kidney disease, pulmonary hypertension, severe hemorrhagic diathesis, and cervical C1/C2 arthritis.21.The participant has had lung surgery which may interfere with bronchoscopy.22.Known history of allergic/hypersensitivity reactions to medications used during and for perioperative care associated with the bronchoscopy/BAL procedures, such as local anesthetics, sedatives, pain control medications.23.The participant is receiving or requires long-term (>4 weeks) immunosuppressive therapy, such as systemic corticosteroids at doses greater than 10 mg/day of prednisone (or its equivalent), mycophenolate mofetil, azathioprine, cyclophosphamide, and rituximab.24.If a participant is receiving anticoagulant or anti-platelet therapy (such as warfarin and clopidogrel), the participant is unwilling to or unable to safely discontinue anticoagulant or anti-platelet therapy within 7 days prior to until at least 24 hours after the BAL procedures. An exception is low-dose aspirin alone which is allowed.**Note: Exclusion criteria #20, #21, #22, #23, and #24 are not applicable to participants who are not required to undergo the bronchoscopy/BAL procedures.

Study Locations

We are planning* on conducting this study in 2 countries around the world.

    • Canada
    • United States of America

Enter your city or postal code to find a location near you.

RESULTS

  • 1.

    Hannibal Clinic

    Hannibal, Missouri
    United States of America

    573-231-3239

    humamfarah@yahoo.com

    miles

  • 2.

    Tampa General Hospital

    Tampa, Florida
    United States of America

    813-363-6677

    tarik_haddad@yahoo.com

    miles

  • 3.

    Kentucky Lung Clinic, PSC

    Hazard, Kentucky
    United States of America

    606-487-1818

    fkoura@hotmail.com

    miles

  • 4.

    Temple University School of Medicine

    Philadelphia, Pennsylvania
    United States of America

    215-707-4679

    friedrich.kueppers@tuhs.temple.edu

    miles

  • 5.

    Medical University of South Carolina (MUSC)

    Charleston, South Carolina
    United States of America

    843-792-8438

    strangec@musc.edu

    miles

  • 6.

    University of Miami

    Miami, Florida
    United States of America

    305-243-2568

    mcampos1@med.miami.edu

    miles

  • 7.

    University of Texas Health Science Center at Tyler

    Tyler, Texas
    United States of America

    903-877-5518

    james.stocks@uthct.edu

    miles

  • 8.

    LHSC - Victoria Hospital

    London, Ontario
    Canada

    519-685-8500

    david.mccormack@lhsc.on.ca

    miles

  • 9.

    Clinical Research Solutions, LLC

    Franklin, Tennessee
    United States of America

    615-610-5592

    drmilstone@crssites.com

    miles

  • 10.

    University of California Davis Health System

    Sacramento, California
    United States of America

    916-703-4093

    bmmorrissey@ucdavis.edu

    miles

  • 11.

    UCLA Medical Center

    Los Angeles, California
    United States of America

    310-206-0396

    ibarjaktarevic@mednet.ucla.edu

    miles

  • 12.

    University of Chicago Medical Center

    Chicago, Illinois
    United States of America

    773-702-1012

    dhogarth@uchicago.edu

    miles

  • 13.

    Cleveland Clinic Florida - Weston

    Weston, Florida
    United States of America

    954-659-6409

    rahaghf@ccf.org

    miles

  • 14.

    St. Joseph's Hospital and Medical Center

    Phoenix, Arizona
    United States of America

    602-406-3825

    rajat.walia@dignityhealth.org

    miles

  • 15.

    Cedars Sinai Medical Center, Division of Pulmonary and Critical Care Medicine

    Los Angeles, California
    United States of America

    310-423-4765

    susan.jackman@cshs.org

    miles

  • 16.

    Pulmonary Critical Care Associates of Baltimore

    Towson, Maryland
    United States of America

    410-494-1662

    dhighfield@pccabpa.com

    miles

*Planning is an intent to conduct this study in the specified countries and is subject to change.